arrow
S

Simonetta Viviani

European Institute of Oncology
H指数:39
被引数:7,179

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term results of brentuximab vedotin and bendamustine for first-line treatment of Hodgkin lymphoma in the elderly (HALO trial)

老年霍奇金淋巴瘤一线治疗中使用 Brentuximab Vedotin 和 Bendamustine 的长期结果(HALO试验)

2026-09-060
OAAI
Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials

III期经典霍奇金淋巴瘤患者在接受2个ABVD疗程后,中期PET(PET-2)德瓦伊评分5分的患者:三项多中心试验的合并分析

2025-10-160
OA
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi
2023-04-014
OAAI
Predictive value on advance hodgkin lymphoma treatment outcome of end-of treatment FDG PET/CT in the HD0607 clinical trial

HD0607临床试验中治疗结束时FDG PET/CT对进展期霍奇金淋巴瘤治疗结局的预测价值

2023-01-041
OA
Early serumTARCreduction predicts prognosis in advanced-stageHodgkinlymphoma patients treated with aPET-adapted strategy
2020-07-3010
PREAI
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials
2017-09-1439
OAAI
Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study
2017-01-2620
OAAI
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale
2014-03-21195
OA
ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned
2011-07-21345
OAAI